Insider Trading Alert - Cepheid And 4 Others Traded By Insiders

Friday, July 8, 2013, 142 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $1.15 to $10,873,958.42.

Highlighted Stocks Traded by Insiders:

Cepheid (CPHD) - FREE Research Report

Miller Andrew who is EVP, CFO at CEPHEID INC bought 860 shares at $17.11 per share for a total value of $8,041.70 on July 3, 2013. Following this transaction, the EVP, CFO owned 1,015 shares meaning that the stake was boosted by 137.6% with the 860 share acquisition.

The shares most recently traded at $35.72, up $0.05, or 0.14% since the insider transaction. Historical insider transactions for Cepheid go as follows:

  • 4-Week # shares sold: 12,468
  • 12-Week # shares sold: 13,050
  • 24-Week # shares sold: 13,197

The average volume for Cepheid has been 485,000 shares per day over the past 30 days. Cepheid has a market cap of $2.3 billion and is part of the technology sector and electronics industry. Shares are up 1.06% year to date as of the close of trading on Friday.

Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical market; and for application in legacy non-clinical market. Currently there are 10 analysts that rate Cepheid a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CPHD - FREE

TheStreet Quant Ratings rates Cepheid as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and increase in net income. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity and a generally disappointing performance in the stock itself. Get the full Cepheid Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Bally Technologies (BYI) - FREE Research Report

David Robbins who is Director at BALLY TECH INC bought 339,473 shares on July 3, 2013. Following this transaction, the Director owned 311,702 shares meaning that the stake was boosted by 1222.4% with the 339,473 share acquisition.

Guido Robert L who is Director at BALLY TECH INC sold 10,811 shares at $58.33 per share for a total value of $632,038.00 on July 3, 2013. Following this transaction, the Director owned 68,223 shares meaning that the stake was reduced by 13.68% with the 10,811 share sell-off.

The shares most recently traded at $58.67, up $0.13, or 0.22% since the insider transactions. Historical insider transactions for Bally Technologies go as follows:

  • 4-Week # shares sold: 9,155
  • 12-Week # shares sold: 105,882
  • 24-Week # shares bought: 25,000
  • 24-Week # shares sold: 121,682

The average volume for Bally Technologies has been 568,500 shares per day over the past 30 days. Bally Technologies has a market cap of $2.2 billion and is part of the services sector and leisure industry. Shares are up 30.93% year to date as of the close of trading on Friday.

Bally Technologies, Inc., a gaming company, engages in the design, manufacture, operation, and distribution of technology-based gaming devices, systems, server-based solutions, custom mobile applications, and interactive applications. The company has a P/E ratio of 18.3. Currently there are 9 analysts that rate Bally Technologies a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BYI - FREE

TheStreet Quant Ratings rates Bally Technologies as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, solid stock price performance, impressive record of earnings per share growth and compelling growth in net income. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Bally Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Dendreon (DNDN) - FREE Research Report

Cox Greg who is VP, Finance at DENDREON CORP sold 888 shares at $4.30 per share for a total value of $3,818.40 on July 3, 2013. Following this transaction, the VP, Finance owned 116,979 shares meaning that the stake was reduced by 0.75% with the 888 share sell-off.

Frohlich Mark W who is EVP, R&D and CMO at DENDREON CORP sold 2,564 shares at $4.30 per share for a total value of $11,025.20 on July 3, 2013. Following this transaction, the EVP, R&D and CMO owned 540,994 shares meaning that the stake was reduced by 0.47% with the 2,564 share sell-off.

Schiffman Gregory T who is CFO, EVP of Finance & Treasure at DENDREON CORP sold 2,564 shares at $4.30 per share for a total value of $11,025.20 on July 3, 2013. Following this transaction, the CFO, EVP of Finance & Treasure owned 445,846 shares meaning that the stake was reduced by 0.57% with the 2,564 share sell-off.

The shares most recently traded at $4.49, up $0.01, or 0.22% since the insider transactions.

The average volume for Dendreon has been 4.2 million shares per day over the past 30 days. Dendreon has a market cap of $677.7 million and is part of the health care sector and drugs industry. Shares are down 18.71% year to date as of the close of trading on Friday.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Currently there are 2 analysts that rate Dendreon a buy, 8 analysts rate it a sell, and 10 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DNDN - FREE

TheStreet Quant Ratings rates Dendreon as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Dendreon Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Akamai Technologies (AKAM) - FREE Research Report

Sagan Paul who is Director at AKAMAI TECH bought 180,669 shares at $14.33 per share for a total value of $1,433,250.00 on July 5, 2013. Following this transaction, the Director owned 847,233 shares meaning that the stake was boosted by 25.21% with the 180,669 share acquisition.

Historical insider transactions for Akamai Technologies go as follows:

  • 4-Week # shares sold: 592
  • 12-Week # shares sold: 10,592
  • 24-Week # shares sold: 10,592

The average volume for Akamai Technologies has been 2.7 million shares per day over the past 30 days. Akamai Technologies has a market cap of $7.6 billion and is part of the technology sector and internet industry. Shares are up 5.18% year to date as of the close of trading on Friday.

Akamai Technologies, Inc. provides content delivery and cloud infrastructure services for accelerating and improving the delivery of content and applications over the Internet in the United States and internationally. The company has a P/E ratio of 33.6. Currently there are 14 analysts that rate Akamai Technologies a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AKAM - FREE

TheStreet Quant Ratings rates Akamai Technologies as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, robust revenue growth and largely solid financial position with reasonable debt levels by most measures. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Akamai Technologies Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

FactSet Research Systems (FDS) - FREE Research Report

Laird Joseph E Jr who is Director at FACTSET RESH sold 1,000 shares at $105.64 per share for a total value of $105,640.00 on July 8, 2013. Following this transaction, the Director owned 3,000 shares meaning that the stake was reduced by 25% with the 1,000 share sell-off.

The shares most recently traded at $105.10, up $1.48, or 1.43% since the insider transaction. Historical insider transactions for FactSet Research Systems go as follows:

  • 4-Week # shares sold: 7,624
  • 12-Week # shares sold: 7,624
  • 24-Week # shares sold: 12,574

The average volume for FactSet Research Systems has been 413,400 shares per day over the past 30 days. FactSet Research Systems has a market cap of $4.5 billion and is part of the technology sector and computer software & services industry. Shares are up 17.67% year to date as of the close of trading on Friday.

FactSet Research Systems Inc. provides financial and economic information to investment community worldwide. The stock currently has a dividend yield of 1.36%. The company has a P/E ratio of 23.6. Currently there are 2 analysts that rate FactSet Research Systems a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FDS - FREE

TheStreet Quant Ratings rates FactSet Research Systems as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full FactSet Research Systems Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Asian Markets Decline in Morning Trading

Asian Markets Decline in Morning Trading

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Verizon Proves Resilient in Sell-Off; Decoding the Facebook Short -- ICYMI

Three Big Factors That Rocked the Stock Market Tuesday

Three Big Factors That Rocked the Stock Market Tuesday

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Dow Tumbles Over 400 Points; S&P 500 and Nasdaq Also Finish Lower

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call

Caterpillar Bulldozes Industrial Sector With Bad News on Earnings Call